Abstract 51P
Background
Four-year outcomes of hypofractionated postmastectomy radiation therapy of 39 Gy in 13. Fractionations to investigate early and four year late side effects of hypofractionated postmastectomy radiation therapy (HFRT-PM) of 39 Gy in 13 fractions over 3 weeks.
Methods
We retrospectively analyzed characteristics and outcomes of patients with stage II to III breast cancer treated with HFRT-PM between February 2019 and February 2023 during the COVID-19 pandemic. The selected patients did not have any previously diagnosed heart or lung disease. Treatment provided in 13 fractions of 3 Gy per fraction. The treatment techniques were applied by using 3-dimensional conformal radiation therapy and IMRT of the chest wall with regional nodal volume if required. The end point was freedom from any grade 3 or higher toxicities.
Results
We identified 730 patients with a median follow-up of 4 year. About two-third of the patient (66.6%) had the disease located in the left side. Regional nodal irradiation was done in 84.1% of patients. In multivariate analysis, regional lymph node involvement (≥4 nodes) was associated with worse locoregional control (hazard ratio, 1.68; 95% confidence interval, 1.06-2.67; P = .03) and overall survival (hazard ratio, 2.16; 95% confidence interval, 1.59-2.95; P < .001). The toxicities were acceptable. After a four-year follow -up, there are no grade 3 or 4 toxicities. The incidence of early skin reactions (13% grade 2) cardiac disorders (1.5%), and symptomatic lung fibrosis (1.7%) was low during follow-up. The cumulative rate of arm lymphedema was 2.1% and considered severe in 40 patients (0.05%).
Conclusions
The early results of this study show that HFRT-PM of 39 Gy in 13 fractions over 3 weeks seems safe, but long-term results need to be observed and highlighting the need for long-term follow-up and for randomized trials for hypofractionated radiation therapy postmastectomy especially for young patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
239P - Elevated baseline C-reactive protein is a prognostic indicator for OS in patients with metastatic non clear cell renal cell carcinoma treated with systemic therapy
Presenter: Ryuichi Mizuno
Session: Poster Display
Resources:
Abstract
240P - Efficacy and safety of first-line combination therapy with ipilimumab + nivolumab for metastatic renal cell carcinoma in a single institution in Japan
Presenter: Naoya Nagaya
Session: Poster Display
Resources:
Abstract
241P - First-line cabozantinib in metastatic renal cell carcinoma (mRCC): A real-world exploratory study from eastern India
Presenter: Tamojit Chaudhuri
Session: Poster Display
Resources:
Abstract
244P - Clinicopathologic feature and treatment outcome of metastatic non clear cell kidney cancer: A single centre experience from India
Presenter: Somnath Roy
Session: Poster Display
Resources:
Abstract
245P - The role of TGF-β in the formation of the protumor phenotype of circulating neutrophils at different stages of renal cancer
Presenter: Ilseya Myagdieva
Session: Poster Display
Resources:
Abstract
246P - Impact of renal impairment on first-line treatment in metastatic urothelial cancer
Presenter: Stephanie Wakeling
Session: Poster Display
Resources:
Abstract
247P - Adjuvant chemoradiotherapy in the management of bladder adenocarcinoma compared to multiple treatment modalities
Presenter: Othman Mohammed
Session: Poster Display
Resources:
Abstract
248P - Screening zinc homeostasis-related genes identifies metallothionein 1H (MT1H) as a potential prognostic biomarker in clear cell renal cell carcinoma (ccRCC)
Presenter: Eyad Al Masoud
Session: Poster Display
Resources:
Abstract
249P - The prognostic utility of Progestogen associated Endometrial protein (PAEP) gene expression in clear cell renal cell carcinoma (ccRCC)
Presenter: Leen Lataifeh
Session: Poster Display
Resources:
Abstract
250P - Impact of adjuvant chemo(radio)therapy in stage I/II testicular seminoma
Presenter: Mahmoud Eleisawy
Session: Poster Display
Resources:
Abstract